The CLARITY survey, the findings of which were published in the Pulmonary Circulation April 2024 issue (link), aimed to collect data on current chronic thromboembolic pulmonary hypertension (CTEPH) diagnosis, treatment, and management, and to identify unmet medical needs. Conducted from September 2021 to May 2022, the survey targeted hospital-based medical specialists via Scientific Societies and other medical organisations and had 212 responses.
Jared Kaltwasser has summarised the findings of the study in an excellent recent article for the AJMC – The American Journal of Managed Care (link), in particular with regard to the very wide regional variability in decisions on treatment eligibility for pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) due to factors such as patient refusal, distal disease, or unfavourable risk profiles. These barriers to access barriers need to be addressed, taking into consideration country-specific health care system factors, including the financing and organisation of care.
